1. Home
  2. ACXP vs MRNS Comparison

ACXP vs MRNS Comparison

Compare ACXP & MRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ACXP
  • MRNS
  • Stock Information
  • Founded
  • ACXP 2017
  • MRNS 2003
  • Country
  • ACXP United States
  • MRNS United States
  • Employees
  • ACXP N/A
  • MRNS N/A
  • Industry
  • ACXP Biotechnology: Pharmaceutical Preparations
  • MRNS Biotechnology: Pharmaceutical Preparations
  • Sector
  • ACXP Health Care
  • MRNS Health Care
  • Exchange
  • ACXP Nasdaq
  • MRNS Nasdaq
  • Market Cap
  • ACXP 31.4M
  • MRNS 29.9M
  • IPO Year
  • ACXP 2021
  • MRNS 2014
  • Fundamental
  • Price
  • ACXP $0.78
  • MRNS $0.55
  • Analyst Decision
  • ACXP Strong Buy
  • MRNS Buy
  • Analyst Count
  • ACXP 1
  • MRNS 12
  • Target Price
  • ACXP $12.00
  • MRNS $4.28
  • AVG Volume (30 Days)
  • ACXP 273.8K
  • MRNS 1.4M
  • Earning Date
  • ACXP 03-14-2025
  • MRNS 03-04-2025
  • Dividend Yield
  • ACXP N/A
  • MRNS N/A
  • EPS Growth
  • ACXP N/A
  • MRNS N/A
  • EPS
  • ACXP N/A
  • MRNS N/A
  • Revenue
  • ACXP N/A
  • MRNS $31,466,000.00
  • Revenue This Year
  • ACXP N/A
  • MRNS $14.97
  • Revenue Next Year
  • ACXP N/A
  • MRNS $57.65
  • P/E Ratio
  • ACXP N/A
  • MRNS N/A
  • Revenue Growth
  • ACXP N/A
  • MRNS 1.63
  • 52 Week Low
  • ACXP $0.68
  • MRNS $0.22
  • 52 Week High
  • ACXP $3.35
  • MRNS $10.50
  • Technical
  • Relative Strength Index (RSI)
  • ACXP 46.10
  • MRNS 70.09
  • Support Level
  • ACXP $0.70
  • MRNS $0.54
  • Resistance Level
  • ACXP $0.82
  • MRNS $0.55
  • Average True Range (ATR)
  • ACXP 0.06
  • MRNS 0.01
  • MACD
  • ACXP 0.01
  • MRNS -0.01
  • Stochastic Oscillator
  • ACXP 40.10
  • MRNS 93.00

About ACXP Acurx Pharmaceuticals Inc.

Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration.

About MRNS Marinus Pharmaceuticals Inc.

Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19-RE.

Share on Social Networks: